Cullinan Therapeutics (CGEM) Profit After Tax (2021 - 2023)
Historic Profit After Tax for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$25.6 million.
- Cullinan Therapeutics' Profit After Tax rose 455.16% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 24057.41%. This contributed to the annual value of -$167.6 million for FY2024, which is 804.25% down from last year.
- As of Q4 2023, Cullinan Therapeutics' Profit After Tax stood at -$25.6 million, which was up 455.16% from -$39.2 million recorded in Q3 2023.
- Cullinan Therapeutics' Profit After Tax's 5-year high stood at $174.9 million during Q2 2022, with a 5-year trough of -$58.1 million in Q1 2023.
- Moreover, its 3-year median value for Profit After Tax was -$25.2 million (2022), whereas its average is -$9.4 million.
- The largest annual percentage gain for Cullinan Therapeutics' Profit After Tax in the last 5 years was 116392.12% (2022), contrasted with its biggest fall of 100852.71% (2022).
- Quarter analysis of 3 years shows Cullinan Therapeutics' Profit After Tax stood at -$34.2 million in 2021, then increased by 21.7% to -$26.8 million in 2022, then grew by 4.55% to -$25.6 million in 2023.
- Its Profit After Tax was -$25.6 million in Q4 2023, compared to -$39.2 million in Q3 2023 and -$32.2 million in Q2 2023.